Overview
Description
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Denmark
Financials
Key metrics
Market capitalisation, EUR | 4,975.41 m |
EPS, EUR | 0.57 |
P/B ratio | 6.50 |
P/E ratio | 39.36 |
Dividend yield | 0.00% |
Income statement (2024)
Revenue, EUR | 742.55 m |
Net income, EUR | 109.30 m |
Profit margin | 14.72% |
What ETF is ALK-Abello A/S in?
There are 30 ETFs which contain ALK-Abello A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of ALK-Abello A/S is the Xtrackers Nordic Net Zero Pathway Paris Aligned UCITS ETF 1C.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.